Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

563

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-Stage Small-Cell Lung Cancer
Small-Cell Lung Cancer

Interventions

DRUG: Tarlatamab
DRUG: Durvalumab

Sponsor

Amgen